<DOC>
	<DOCNO>NCT02910414</DOCNO>
	<brief_summary>The TARGET BP I Trial randomize , double-blinded , multi-center , international , sham-procedure control trial , compare renal denervation perform Peregrine System Kit treatment group sham control group ( without renal denervation - alcohol infusion ) . Subjects randomized 2:1 fashion treatment versus sham control via central randomization .</brief_summary>
	<brief_title>TARGET BP I Clinical Trial</brief_title>
	<detailed_description>The TARGET BP I Trial randomize , double-blinded , multi-center , international , sham-procedure control trial , compare renal denervation perform Peregrine System Kit treatment group sham control group ( without renal denervation - alcohol infusion ) . Subjects randomized 2:1 fashion treatment versus sham control via central randomization . The TARGET BP I clinical trial use percutaneous catheter deliver small amount alcohol ( neurolytic agent ) . The patient population trial comparable use renal denervation study , also incorporate lesson learn recent trial renal denervation . This enable study optimize patient population stand benefit intervention , manner reduces possible study bias . This trial intend evaluate safety efficacy Peregrine Catheter use deliver 0.6 mL volume alcohol perivascular area respective renal artery patient adequately manage oral antihypertensive medication .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>1 . Subject &gt; 18 ≤ 75 year old time enrollment . 2 . Subjects maintain antihypertension medication regimen 25 medication ( labelled hypertension ) least four week ( 28 day ) prior randomization . Two antihypertensive medication must least 50 % maximally label dose prior plan renal denervation treatment . In subject two medication , least one must diuretic second ACE inhibitor angiotensin receptor blocker ( ARB ) . All subject must currently , documentation fail tolerated diuretic . For patient two nondiuretic antihypertensive medication either fail unable tolerate diuretic , two medication must consist ACE ARB Calcium Channel blocker ( CCB ) . Note : following class antihypertensive agent would count towards minimum number agent : ACE inhibitor , ARB , calcium channel blocker , thiazide diuretic , loop diuretic , aldosterone antagonist , betablockers , centrally active agent , alpha receptor blocker , direct vasodilator , direct renin inhibitor , hydralazine . 3 . Patient agree trial procedure perform , comply medication regimen able willing comply followup visit . 4 . Patient willing provide write informed consent . 5 . Meets blood pressure criterion four week stable medication monitoring phase complete , prior procedure : 1 . Mean 3 measurement office systolic Blood Pressure ≥ 150 mmHg ≤ 180 mmHg , AND 2 . Daytime mean systolic Ambulatory Blood Pressure Measurement ( ABPM ) ≥ 140 mmHg ≤ 170 mmHg . 6 . Investigator judge subject manage safely 12 week ( 4 week pretreatment plus 8 week posttreatment ) without change current antihypertensive treatment regimen . 1 . Patients chronic atrial fibrillation . 2 . Patient document secondary hypertension , include limited : Cushing 's disease Cushing 's Syndrome , hyperaldosteronism , pheochromocytoma , document obstructive sleep apnea , document thyroid parathyroid abnormality etc. , onset hypertension prior age 18 . Note : document evaluation secondary hypertension require . 3 . Renal artery stenosis ≥ 50 % diameter stenosis , aneurysm ( ) 4 . History previous stenting balloon angioplasty renal artery 5 . History preeclampsia 6 . Orthostatic hypotension baseline , document history orthostatic hypotension within last 12 month , define drop blood pressure great 20 mmHg systolic BP and/or 10 mmHg diastolic BP within 3 minute upon stand sit lie faceup ( supine ) position 7 . Renal artery anatomy assess imaging ( CTA , MRA renal angiogram ) meeting follow criterion : 1 . Main renal artery diameter &lt; 4 mm &gt; 7 mm length &lt; 11 mm ( Note : patient one main eligible renal artery per side exclude ) , 2 . Accessory renal artery diameter &gt; 2 mm , 3 . Excessive renal artery tortuosity base Investigator judgment , 4 . Moderate severe , diffuse renal artery calcification , 5 . Renal anatomic vascular abnormality ( assessed renal imaging ) would increase risk renal catheterization , and/or 6 . Fibromuscular dysplasia 8 . Occlusive peripheral vascular disease would preclude percutaneous access procedure . 9 . Patient known unilateral nonfunctioning kidney unequal renal size ( &gt; 2 cm difference renal length kidney ) . 10 . Single kidney , kidney tumor , urinary tract obstruction , anatomic abnormality . Note : Simple renal cyst exclusion . 11 . Previous renal denervation . 12 . History renal transplantation . 13 . History pyelonephritis within 6 month . 14 . History recurrent ( &gt; one episode ) kidney stone , history kidney stone within last year . 15 . Estimated eGFR ( CKDEpi formula ) &lt; 45 mL/min per 1.73 m2 , chronic renal replacement therapy . 16 . Unexplained hypokalemia ( i.e . K &lt; 3.5 mEq/L subject potassiumwasting diuretic ) . Note : Patients hypokalemia potassiumwasting diuretic another potential reason hypokalemia discuss Medical Monitor . Note : Hypokalemia , know etiology ( i.e . diuretic effect ) , correct proceeding procedure . 17 . Patient ABPM device use due arm size ( &gt; 40 cm arm circumference ) reason identify Investigator study coordinator . 18 . Patient severe cardiac valve stenosis , opinion Investigator , significant reduction blood pressure contraindicate . 19 . Patient heart failure ( NYHA Class II IV ) ejection fraction ≤ 35 % . 20 . Known primary secondary pulmonary hypertension . 21 . Active infection . 22 . Type 1 diabetes mellitus . 23 . Patient require chronic oxygen support severe COPD . 24 . Patient known hypersensitivity contrast agent adequately premedicated 25 . A known hypersensitivity Dehydrated Alcohol Injection , USP . 26 . Platelet count &lt; 75,000/microliter and/or know bleed diathesis coagulopathy time screen . 27 . Receiving anticoagulant drug ( e.g. , warfarin , dabigatran , rivaroxaban , apixaban , edoxaban , low molecular weight heparin ) , opinion Investigator , would affect safety trial procedure . Use antiplatelet drug aspirin and/or thienopyridines ( e.g. , clopidogrel ) permit . 28 . Patient current problem substance abuse ( e.g . alcohol , illegal drug , etc. ) . 29 . Patient steroid immunosuppressant dos , immunosuppressant therapy , except nasal pulmonary inhalant . 30 . Patient history myocardial infarction , unstable angina pectoris , stroke 6 month prior enrollment . 31 . Pregnant nursing planning become pregnant trial time period . Note : If subject childbearing potential , define protocol , agree use contraception . 32 . Any acute chronic condition investigator believe adversely affect ability interpret data prevent subject complete trial procedure , life expectancy &lt; 12 month . 33 . Patient participate agree participate investigational drug device trial participation study complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>